ROCKVILLE, Md., Sept. 11,
2023 /PRNewswire/ -- Shuttle Pharmaceuticals
Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage
specialty pharmaceutical company focused on improving the outcomes
of cancer patients treated with radiation therapy (RT), today
announced the expansion of its patent portfolio following the
issuance of a Canadian patent for its Histone Deacetylase (HDAC)
inhibitor platform technology titled "Dual Function Molecules for
Histone Deacetylase Inhibition and Ataxia Telangiectasia Mutated
(ATM) Activation and Methods of Use Thereof."
HDAC inhibitors have been described as "a novel class of drugs
that target enzymes involved in regulation of critical cellular
functions that can inhibit cancer growth and activate cellular
immunity," according to Scott
Grindrod, PhD, lead inventor and Laboratory Director at
Shuttle Pharmaceuticals.
The Company's HDAC pre-clinical inhibitor platform includes:
- SP-2-225 is Shuttle Pharma's pre-clinical Class IIb selective
HDAC inhibitor that affects histone deacetylase HDAC6. SP-2-225 has
effects on the regulation of the immune system. The interactions of
radiation therapy with the immune response to cancers are of great
current interest, offering insight into potential mechanisms for
primary site and metastatic cancer treatment. For this reason,
Shuttle Pharma selected SP-2-225 as the candidate lead HDAC
inhibitor for preclinical development. Shuttle Pharma is advancing
drug manufacture and IND-enabling studies with the goal of enabling
a Phase I clinical trial in 2024. With the introduction of
check-point inhibitors, CAR-T therapies and personalized medicine
in cancer, regulation of the immune response following RT continues
to be of significant clinical and commercial interest.
- SP-1-161 is Shuttle Pharma's pre-clinical candidate lead HDAC
inhibitor, radiation sensitizing candidate product. This pan HDAC
inhibitor initiates the mutated ataxia-telangiectasia response
pathway. Using rational drug design, Shuttle Pharma discovered HDAC
inhibitors and ATM activators capable of radiation sensitizing
cancer cells and protecting normal cells. The candidate drug may
serve as a direct chemotherapeutic agent or as a radiation
sensitizer for treating cancers. In preclinical studies, SP-1-161
protected normal breast epithelial cells (184A1) following exposure
to ionizing radiation while increasing sensitivity of breast cancer
cells (MCF7). SP-1-161 provides this dual function in a single
molecule and this molecule is differentiated from other HDAC
inhibitors by treatment of cancers while protecting normal
cells.
- SP-1-303 is Shuttle Pharma's pre-clinical selective Class I
HDAC inhibitor that preferentially affects histone deacetylases
HDAC1 and HDAC3 and is a member of the Class I HDAC family.
SP-1-303 data show direct cellular toxicity in estrogen receptor
(ER) positive breast cancer cells.
"We continue to expand our patent portfolio surrounding our HDAC
inhibitor platform," stated Anatoly
Dritschilo, M.D., CEO of Shuttle Pharmaceuticals. "We look
forward to advancing our developments by providing dual function
compounds that may inhibit HDAC and activate ATM to treat certain
cancers, such as breast, multiple myeloma and lung, as well as
neurological disorders, and immunological disorders. Our objective
is to improve patient outcomes by increasing sensitivity to
radiation while protecting normal tissues."
About Shuttle Pharmaceuticals
Founded in 2012 by faculty members of the Georgetown
University Medical Center, Shuttle Pharmaceuticals is a
discovery and development stage specialty pharmaceutical company
focused on improving the outcomes for cancer patients treated with
radiation therapy (RT). Our mission is to improve the lives of
cancer patients by developing therapies that are designed to
maximize the effectiveness of RT while limiting the side effects of
radiation in cancer treatment. Although RT is a proven modality for
treating cancers, by developing radiation sensitizers, we aim to
increase cancer cure rates, prolong patient survival and improve
quality of life when used as a primary treatment or in combination
with surgery, chemotherapy and immunotherapy. For more information,
please visit our website at www.shuttlepharma.com.
Safe Harbor Statement
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
"forward-looking statements." These statements include, but are not
limited to, statements concerning the development of our company.
The words "anticipate," "believe," "continue," "could," "estimate,"
"expect," "intend," "may," "plan," "potential," "predict,"
"project," "should," "target," "will," "would" and similar
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. Actual results may differ materially from those
indicated by such forward-looking statements as a result of various
important factors, including factors discussed in the "Risk
Factors" section of Shuttle Pharma's Annual Report on Form
10-K for the year ended December 31,
2022, filed with the SEC on March 15,
2023, its Quarterly Reports on Form 10-Q for the periods
ended March 31, 2023 and June 30, 2023, filed with the SEC on May 25, 2023 and August
14, 2023, respectively, as well other SEC filings. Any
forward-looking statements contained in this press release speak
only as of the date hereof and, except as required by federal
securities laws, Shuttle Pharmaceuticals specifically disclaims any
obligation to update any forward-looking statement, whether as a
result of new information, future events or otherwise.
Shuttle Pharmaceuticals
Anatoly Dritschilo, M.D., CEO
240-403-4212
info@shuttlepharma.com
Investor Contacts
Lytham Partners, LLC
Robert Blum
602-889-9700
shph@lythampartners.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/shuttle-pharma-expands-patent-coverage-on-hdac-inhibitor-platform-301922874.html
SOURCE Shuttle Pharmaceuticals Holdings, Inc.